$PRVA
Privia Health Group, Inc.

2021 Q4 Form 10-Q Financial Statement

#000175965521000040 Filed on November 08, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $275.3M $251.5M $213.7M
YoY Change 28.84% 21.41%
Cost Of Revenue $250.4M $225.4M $190.3M
YoY Change 31.61% 21.38%
Gross Profit $24.89M $26.16M $23.40M
YoY Change 6.36% 21.67%
Gross Profit Margin 9.04% 10.4% 10.95%
Selling, General & Admin $43.12M $38.50M $18.78M
YoY Change 129.59% 208.06%
% of Gross Profit 173.27% 147.19% 80.27%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.113M $466.0K $452.0K
YoY Change 146.24% 1.97%
% of Gross Profit 4.47% 1.78% 1.93%
Operating Expenses $44.23M $264.3M $19.24M
YoY Change 129.95% 33.08%
Operating Profit -$19.35M -$12.81M $4.162M
YoY Change -564.85% -249.94%
Interest Expense -$185.0K $300.0K -$437.0K
YoY Change -57.67% -40.0%
% of Operating Profit -10.5%
Other Income/Expense, Net
YoY Change
Pretax Income -$19.53M -$13.10M $3.725M
YoY Change -624.35% -262.97%
Income Tax -$7.643M -$2.200M -$54.00K
% Of Pretax Income -1.45%
Net Earnings -$11.98M -$9.115M $3.864M
YoY Change -410.02% -154.63%
Net Earnings / Revenue -4.35% -3.62% 1.81%
Basic Earnings Per Share -$0.09
Diluted Earnings Per Share -$111.9K -$0.09 $37.59K
COMMON SHARES
Basic Shares Outstanding 106.5M shares 105.9M shares
Diluted Shares Outstanding 105.9M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $320.6M $362.1M
YoY Change
Cash & Equivalents $320.6M $362.1M $84.63M
Short-Term Investments
Other Short-Term Assets $8.697M $8.928M
YoY Change
Inventory
Prepaid Expenses
Receivables $117.4M $98.38M $99.12M
Other Receivables $0.00 $0.00
Total Short-Term Assets $446.7M $469.4M $190.1M
YoY Change 134.99%
LONG-TERM ASSETS
Property, Plant & Equipment $4.502M $4.341M $4.814M
YoY Change -6.48%
Goodwill $127.9M $118.7M $118.7M
YoY Change 7.78%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.521M $3.384M $4.475M
YoY Change 1.03%
Total Long-Term Assets $239.7M $162.6M $138.9M
YoY Change 72.59%
TOTAL ASSETS
Total Short-Term Assets $446.7M $469.4M $190.1M
Total Long-Term Assets $239.7M $162.6M $138.9M
Total Assets $686.4M $632.1M $329.0M
YoY Change 108.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.973M $3.266M $5.235M
YoY Change -43.21%
Accrued Expenses $45.91M $31.30M $31.19M
YoY Change 47.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $875.0K $875.0K
YoY Change
Total Short-Term Liabilities $190.5M $187.2M $146.9M
YoY Change 29.62%
LONG-TERM LIABILITIES
Long-Term Debt $31.69M $31.66M
YoY Change
Other Long-Term Liabilities $3.000M $333.0K $5.595M
YoY Change -46.38%
Total Long-Term Liabilities $45.73M $39.82M $38.38M
YoY Change 19.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $190.5M $187.2M $146.9M
Total Long-Term Liabilities $45.73M $39.82M $38.38M
Total Liabilities $236.2M $227.1M $185.3M
YoY Change 27.45%
SHAREHOLDERS EQUITY
Retained Earnings -$208.1M -$196.1M -$19.88M
YoY Change 946.93%
Common Stock $1.078M $1.062M $960.0K
YoY Change 12.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $426.9M $410.6M $146.7M
YoY Change
Total Liabilities & Shareholders Equity $686.4M $632.1M $329.0M
YoY Change 108.64%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income -$11.98M -$9.115M $3.864M
YoY Change -410.02% -154.63%
Depreciation, Depletion And Amortization $1.113M $466.0K $452.0K
YoY Change 146.24% 1.97%
Cash From Operating Activities -$12.32M $62.65M -$3.339M
YoY Change 268.97% 76.28%
INVESTING ACTIVITIES
Capital Expenditures -$151.0K -$197.0K $0.00
YoY Change 19600.0%
Acquisitions
YoY Change
Other Investing Activities -$32.23M $0.00
YoY Change
Cash From Investing Activities -$32.38M -$197.0K $0.00
YoY Change 19600.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.164M -93.00K -219.0K
YoY Change -1544.75% -99.08%
NET CHANGE
Cash From Operating Activities -12.32M 62.65M -3.339M
Cash From Investing Activities -32.38M -197.0K 0.000
Cash From Financing Activities 3.164M -93.00K -219.0K
Net Change In Cash -41.54M 62.36M -3.558M
YoY Change 1067.37% 145.24%
FREE CASH FLOW
Cash From Operating Activities -$12.32M $62.65M -$3.339M
Capital Expenditures -$151.0K -$197.0K $0.00
Free Cash Flow -$12.17M $62.85M -$3.339M
YoY Change 264.45% 76.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001759655
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 USD
CY2020Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40365
prva Number Of Ms Os Where The Company Is At Lease The Majority Owner
NumberOfMSOsWhereTheCompanyIsAtLeaseTheMajorityOwner
2 company
dei Entity Registrant Name
EntityRegistrantName
Privia Health Group, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3599420
dei Entity Address Address Line1
EntityAddressAddressLine1
950 N. Glebe Rd.,
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 700
dei Entity Address City Or Town
EntityAddressCityOrTown
Arlington,
dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
22203
dei City Area Code
CityAreaCode
571
dei Local Phone Number
LocalPhoneNumber
366-8850
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
PRVA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5980000 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
106498546 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
362112000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84633000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
98384000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
99118000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8928000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6333000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
469424000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
190084000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4341000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4814000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5377000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5498000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
118663000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
118663000 USD
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
25374000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
4953000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3384000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4475000 USD
CY2021Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
162637000 USD
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
138885000 USD
CY2021Q3 us-gaap Assets
Assets
632061000 USD
CY2020Q4 us-gaap Assets
Assets
328969000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3266000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5235000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31303000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31185000 USD
CY2021Q3 prva Physician And Practice Liability Current
PhysicianAndPracticeLiabilityCurrent
144996000 USD
CY2020Q4 prva Physician And Practice Liability Current
PhysicianAndPracticeLiabilityCurrent
106811000 USD
CY2021Q3 us-gaap Notes Payable Current
NotesPayableCurrent
875000 USD
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
875000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2200000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 USD
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4602000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2832000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
187242000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
146938000 USD
CY2021Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
31664000 USD
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
32784000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7827000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
333000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5595000 USD
CY2021Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
39824000 USD
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
38379000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
227066000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
185317000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
106234792 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
106234792 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95985817 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95985817 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
1062000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
960000 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
605667000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
165666000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-196129000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19878000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
410600000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
146748000 USD
CY2021Q3 us-gaap Minority Interest
MinorityInterest
-5605000 USD
CY2020Q4 us-gaap Minority Interest
MinorityInterest
-3096000 USD
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
404995000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
143652000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
632061000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
328969000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
251524000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
207170000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
690887000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
603376000 USD
CY2021Q3 prva Physician And Practice Expense
PhysicianAndPracticeExpense
190055000 USD
CY2020Q3 prva Physician And Practice Expense
PhysicianAndPracticeExpense
160432000 USD
prva Physician And Practice Expense
PhysicianAndPracticeExpense
521105000 USD
prva Physician And Practice Expense
PhysicianAndPracticeExpense
467059000 USD
CY2021Q3 prva Cost Of Platform
CostOfPlatform
35314000 USD
CY2020Q3 prva Cost Of Platform
CostOfPlatform
25241000 USD
prva Cost Of Platform
CostOfPlatform
131007000 USD
prva Cost Of Platform
CostOfPlatform
77133000 USD
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4588000 USD
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2709000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
18950000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7381000 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33910000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9788000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
216563000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29196000 USD
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
466000 USD
CY2020Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
457000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1351000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1389000 USD
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
264333000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
198627000 USD
us-gaap Operating Expenses
OperatingExpenses
888976000 USD
us-gaap Operating Expenses
OperatingExpenses
582158000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12809000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
8543000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-198089000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
21218000 USD
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-292000 USD
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-504000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-885000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1480000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13101000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8039000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-198974000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2509000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
19738000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2210000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-8561000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-20214000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7387000 USD
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-10891000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
16600000 USD
us-gaap Profit Loss
ProfitLoss
-178760000 USD
us-gaap Profit Loss
ProfitLoss
27125000 USD
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1776000 USD
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-85000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-255000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9115000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
16685000 USD
us-gaap Net Income Loss
NetIncomeLoss
-176251000 USD
prva Unusual Or Infrequent Items Or Both Social Security Taxes Repayment Deferral Period
UnusualOrInfrequentItemsOrBothSocialSecurityTaxesRepaymentDeferralPeriod
P2Y
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105896622 shares
us-gaap Net Income Loss
NetIncomeLoss
27380000 USD
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.29
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
105896622 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95950929 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95950929 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101576775 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101576775 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95945804 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95945804 shares
prva Unusual Or Infrequent Items Or Both Social Security Tax Repayment Percent Remainder Of Fiscal Year
UnusualOrInfrequentItemsOrBothSocialSecurityTaxRepaymentPercentRemainderOfFiscalYear
0.50
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
107456000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
121000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
5329000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
112906000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
121000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
5196000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
118223000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
121000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
108000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
16600000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
135052000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
143652000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
101000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
5616000 USD
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
149369000 USD
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
210994000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
33000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
202560000 USD
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-173485000 USD
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
389471000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
615000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25800000 USD
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-10891000 USD
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
404995000 USD
us-gaap Profit Loss
ProfitLoss
-178760000 USD
us-gaap Profit Loss
ProfitLoss
27125000 USD
us-gaap Depreciation
Depreciation
869000 USD
us-gaap Depreciation
Depreciation
895000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
482000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
483000 USD
prva Amortization Addition Of Debt Issuance Costs
AmortizationAdditionOfDebtIssuanceCosts
120000 USD
prva Amortization Addition Of Debt Issuance Costs
AmortizationAdditionOfDebtIssuanceCosts
100000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
228461000 USD
prva Unusual Or Infrequent Items Or Both Social Security Tax Repayment Percent Year One
UnusualOrInfrequentItemsOrBothSocialSecurityTaxRepaymentPercentYearOne
0.50
us-gaap Share Based Compensation
ShareBasedCompensation
363000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-20421000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-7770000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-734000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10138000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7972000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1570000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1091000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-2242000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2064000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2459000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
118000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4061000 USD
prva Increase Decrease Physician And Practice Liability
IncreaseDecreasePhysicianAndPracticeLiability
38185000 USD
prva Increase Decrease Physician And Practice Liability
IncreaseDecreasePhysicianAndPracticeLiability
30883000 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1770000 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
815000 USD
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
10027000 USD
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-5262000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
404000 USD
CY2021Q3 prva Number Of Markets In Which Entity Operates
NumberOfMarketsInWhichEntityOperates
6 market
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
67378000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
42230000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
396000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
380000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-396000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-380000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
223686000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
12691000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
656000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
656000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
648000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
108000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
490000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
10000000 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
10000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
210497000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-548000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
277479000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41302000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84633000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46889000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
362112000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88191000 USD
us-gaap Interest Paid Net
InterestPaidNet
855000 USD
us-gaap Interest Paid Net
InterestPaidNet
1599000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
451000 USD
CY2021Q3 prva Social Security Taxes Payable
SocialSecurityTaxesPayable
1600000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
371000 USD
prva Management Services Organization Ownership Percentage
ManagementServicesOrganizationOwnershipPercentage
1
us-gaap Use Of Estimates
UseOfEstimates
Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure. On an on-going basis we evaluate significant estimates and assumptions, including, but not limited to, revenue recognition, stock-based compensation, estimated useful lives of assets, intangible assets subject to amortization, and the computation of income taxes. Future events and their effects cannot be predicted with certainty; accordingly, the Company’s accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of the financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as the Company’s operating environment changes. Management evaluates and updates assumptions and estimates on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions.
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
prva Unusual Or Infrequent Items Or Both Grants Received
UnusualOrInfrequentItemsOrBothGrantsReceived
13300000 USD
prva Unusual Or Infrequent Items Or Both Grants Received
UnusualOrInfrequentItemsOrBothGrantsReceived
0 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
251524000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
207170000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
690887000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
603376000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
98384000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
99118000 USD
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4832000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2759000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2759000 USD
prva Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
3161000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1088000 USD
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4832000 USD
CY2021Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
200000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1100000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
118700000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
118700000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
9900000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4402000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
9900000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3920000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4402000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3920000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5498000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5980000 USD
us-gaap Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
P10Y
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000 USD
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
160000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
643000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
643000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
559000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
393000 USD
CY2021Q3 prva Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
3100000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5498000 USD
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
475000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
1406000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
1629000 USD
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.035
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
549000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2213000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2261000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2274000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2237000 USD
CY2021Q3 prva Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
1407000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10941000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
901000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
10040000 USD
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
10418000 USD
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7367000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6987000 USD
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3026000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2173000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4341000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4814000 USD
CY2021Q3 prva Accrued Employee Benefits And Compensation Current
AccruedEmployeeBenefitsAndCompensationCurrent
5587000 USD
CY2020Q4 prva Accrued Employee Benefits And Compensation Current
AccruedEmployeeBenefitsAndCompensationCurrent
6167000 USD
CY2021Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
7903000 USD
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
17813000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
14600000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31303000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31185000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
300000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
500000 USD
us-gaap Interest Expense
InterestExpense
900000 USD
us-gaap Interest Expense
InterestExpense
1500000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
100000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
100000 USD
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.010
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
23.00
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
62300000 USD
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P4Y
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
219000 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
875000 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
875000 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1313000 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
1750000 USD
CY2021Q3 prva Long Term Debt Maturities Repayments Of Principal After Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour
28437000 USD
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
33469000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2200000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-8600000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-20200000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7400000 USD
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.097
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
172547 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
18300959 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.01
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.34
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M25D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3730717 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
23.16
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.58
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
328323 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.11
prva Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
0.48
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
3.75
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
21530806 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.61
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.91
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M3D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
12272394 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.01
CY2021Q3 prva Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
0.34
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3D
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25800000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
228500000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000 USD
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
119100000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25800000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
121000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
228461000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
363000 USD
prva Number Of Institutions In Which Company Holds Its Cash And Cash Equivalents
NumberOfInstitutionsInWhichCompanyHoldsItsCashAndCashEquivalents
2 institution
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9115000 USD
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95950929 shares
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
16685000 USD
us-gaap Net Income Loss
NetIncomeLoss
-176251000 USD
us-gaap Net Income Loss
NetIncomeLoss
27380000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105896622 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
105896622 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95950929 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101576775 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101576775 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95945804 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95945804 shares
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.29
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20352659 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17952492 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20410709 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17977529 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20352659 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17952492 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20410709 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17977529 shares

Files In Submission

Name View Source Status
0001759655-21-000040-index-headers.html Edgar Link pending
0001759655-21-000040-index.html Edgar Link pending
0001759655-21-000040.txt Edgar Link pending
0001759655-21-000040-xbrl.zip Edgar Link pending
exhibit1011-amendmentno1to.htm Edgar Link pending
exhibit311-3q21.htm Edgar Link pending
exhibit312-3q21.htm Edgar Link pending
exhibit321-3q21.htm Edgar Link pending
exhibit322-3q21.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
prva-20210930.htm Edgar Link pending
prva-20210930.xsd Edgar Link pending
prva-20210930_cal.xml Edgar Link unprocessable
prva-20210930_def.xml Edgar Link unprocessable
prva-20210930_htm.xml Edgar Link completed
prva-20210930_lab.xml Edgar Link unprocessable
prva-20210930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending